Medicine:202-CoV
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
202-CoV is a COVID-19 vaccine candidate developed by Shanghai Zerun Biotechnology Co., Ltd., Walvax Biotech.[1][2][3] It is one of several candidates under development by Walvax.
Development
In May 2020, the Bill & Melinda Gates Foundation awarded Shanghai Zerun Biotechnology a $1,000,000 USD vaccine development grant to "support research and development for COVID-19 response".[4]
In July 2021, the Coalition for Epidemic Preparedness Innovations (CEPI) announced that it had partnered with Shanghai Zerun Biotechnology and its parent company, Walvax Biotech, to develop COVID-19 vaccine candidates against both the original strain of SARS-CoV-2 and its newer variants.[3] As of October 2022, CEPI had provided up to $25.1 million USD towards 202-CoV, but had ceased further funding.[5] The chimeric protein candidate remains in Phase I clinical trials.
References
- ↑ Clinical trial number NCT04982068 for "Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)" at ClinicalTrials.gov
- ↑ Clinical trial number NCT04990544 for "Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)" at ClinicalTrials.gov
- ↑ 3.0 3.1 "CEPI partners with Shanghai Zerun Biotech to develop COVID-19 variant vaccine". Coalition for Epidemic Preparedness Innovations. 21 July 2021. https://cepi.net/news_cepi/cepi-partners-with-shanghai-zerun-biotech-to-develop-covid-19-variant-vaccine/.
- ↑ "Shanghai Zerun Biotechnology Co., Ltd." (in en). May 2020. https://www.gatesfoundation.org/about/committed-grants/2020/05/inv006445.
- ↑ "Our portfolio" (in en-US). https://cepi.net/research_dev/our-portfolio/.
 |
